| Literature DB >> 15785755 |
K Nosho1, H Yamamoto, Y Adachi, T Endo, Y Hinoda, K Imai.
Abstract
It is generally accepted that most colorectal carcinomas arise in pre-existing adenomas. Morphologically, colorectal adenomas can be divided into two groups, protruded type and flat type. The aim of this study was to clarify relevant alterations of gene expression associated with the early stage of colorectal carcinogenesis. Using cDNA array, we analysed the expression profiles of 550 cancer-related genes in 36 colorectal adenomas (18 flat-type and 18 protruded-type adenomas) and 14 early invasive carcinomas. Among the 550 genes, we chose 32 genes the average expression levels of which were at least three-fold up- or downregulated in tumour tissues compared with levels in matched normal tissues. A total of 13 and 19 genes were identified as up- and downregulated genes in tumour tissues, respectively. Among the upregulated genes, the average expression levels of E1AF, bone morphogenic protein (BMP)-4, insulin-like growth factor (IGF)-2, inducible nitric oxide synthase (iNOS), tissue inhibitors of metalloproteinase (TIMP)-1, Smad4, and nm23 in tumour tissues were over five times higher than those in matched normal tissues. Colorectal adenomas and early invasive carcinomas were divided into two major clusters by clustering analysis. Moreover, flat- and protruded-type adenomas were divided into two major clusters by clustering analysis. The expression profiles obtained by the cDNA array clearly indicate that colorectal adenomas and early invasive carcinomas have specific expression profiles. Likewise, the gene expression profiles of flat- and protruded-type adenomas are different. These results indicate that molecular classification of early colorectal tumours by a cDNA array is feasible.Entities:
Mesh:
Year: 2005 PMID: 15785755 PMCID: PMC2361982 DOI: 10.1038/sj.bjc.6602442
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Clinicopathological characteristics of patients with colorectal tumour
|
| |||
|---|---|---|---|
|
|
|
|
|
| Age (years, mean±s.d.) | 69.1±7.3 | 67.9±5.8 | 71.1±4.9 |
| Size (mm, mean±s.d.) | 25.7±10.0 | 10.5±5.4 | 14.2±12.7 |
| Gender | |||
| Male | 8 | 11 | 13 |
| Female | 6 | 7 | 5 |
| Location | |||
| Proximal | 9 | 5 | 10 |
| Distal | 5 | 13 | 8 |
Average expression levels of E1AF, BMP4, IGF-2, iNOS, TIMP-1, Smad4, and nm23 genes in tumour tissues were over five times higher than those in the matched normal tissues
|
|
|
|
|---|---|---|
| E1AF | Transcription | 8.11 |
| BMP4 | Growth factor | 7.64 |
| IGF-2 | Growth factor | 6.80 |
| iNOS | Angiogenesis | 6.55 |
| TIMP-1 | Inhibitor of MMPs | 6.39 |
| Smad4 | Tumour suppressor | 6.03 |
| nm23 | Tumour suppressor | 5.33 |
T average=average expression levels in tumour tissues; N average,=average expression levels in matched normal tissues. The average of three experiments is shown.
Figure 1Reverse transcriptase–polymerase chain reaction analysis of mRNA expression for IGF-2, E1AF, and iNOS in colorectal tumour tissues. T and N, matched samples from tumour and nontumour tissue, respectively. Cases 1–4 are colorectal adenomas and cases 5–8 are colorectal carcinomas (pT1).
Figure 2A two-dimensional hierarchical clustering of 32 genes across 50 colorectal tumours. The colour in each well represents relative expression of each gene (vertical axis) in each paired sample (horizontal axis); red, increased in tumour tissues; green, decreased in the tumour tissues. In the sample axis, early invasive carcinomas and adenomas were separated into two different trunks. In the gene axis, 32 genes were clustered in different branches according to their similarity; the shorter the branches, the greater the similarity. In adenomas, subclusters of flat type and protruded type were selected for further analysis (see Figure 3).
Genes the expression levels of which differed significantly in the early invasive carcinoma group and the adenoma group (Mann–Whitney U-test)
|
|
|
|
| |
|---|---|---|---|---|
| Eph | M18391 | Cell signalling | 0.0342 | CA<AD |
| Gp130 | M57230 | Cell signalling | 0.0122 | CA<AD |
| GST-II | U77604 | DNA repair or protection | 0.0108 | CA<AD |
| Rho 8 | X95282 | Cell signalling | 0.0069 | CA<AD |
| MUC-2 | M74027 | Glycoprotein | 0.0046 | CA<AD |
| Ras-GAP | AF051311 | Cell signalling | 0.0035 | CA<AD |
| P120 | AF062324 | Cell signalling | 0.0029 | CA<AD |
| MDR1 | AF016535 | Glycoprotein | 0.0019 | CA<AD |
| M94151 | Cell adhesion | 0.0014 | CA<AD | |
| Egr-2 | X53700 | Transcription | 0.0011 | CA<AD |
| PMS1 | U13695 | DNA repair or protection | 0.0002 | CA<AD |
| GAK | D88435 | Cell signalling | 0.0001 | CA<AD |
| IGF-2 | M29645 | Growth factor | 0.0491 | CA>AD |
| E1AF | D12765 | Transcription | 0.0187 | CA>AD |
| iNOS | AB022318 | Angiogenesis | 0.0084 | CA>AD |
| Rho GDI | L20688 | Cell signalling | 0.0002 | CA>AD |
| GSTP1 | X06547 | DNA repair or protection | <0.0001 | CA>AD |
| c-jun | J04111 | Oncogene | <0.0001 | CA>AD |
| ECGF1 | M63193 | Growth factor | <0.0001 | CA>AD |
| nm23 | X17620 | Tumour suppressor | <0.0001 | CA>AD |
| Smad4 | U44378 | Tumour suppressor | <0.0001 | CA>AD |
| TIMP1 | X03124 | Extracellular matrix-Degrading enzymes | <0.0001 | CA>AD |
| BMP-4 | D30751 | Growth factor | 0.7494 | |
| Cdc42 | M57298 | Cell cycle | 0.65 | |
| Erk1 | X60188 | Cell signalling | 0.2101 | |
| FAK | L13616 | Cell signalling | 0.0878 | |
| Galectin-1 | J04456 | Extracellular matrix-degrading enzymes | 0.136 | |
| HLA-DQ | U77589 | Human leucocyte antigen | 0.8289 | |
| Laminin | D37766 | Cell signalling | 0.7134 | |
| MMP-15 | Z48482 | Extracellular matrix-degrading enzymes | 0.8289 | |
| Mucin 3 | AF143371 | Glycoprotein | 0.2897 | |
| P21 | U03106 | CDK inhibitor | 0.1734 | |
CA=early invasive carcinoma group; AD=adenoma group.
Figure 3A two-dimensional hierarchical clustering of 32 genes across 36 colorectal adenomas. The colour in each well represents relative expression of each gene (vertical axis) in each paired sample (horizontal axis); red, increased in adenoma tissues; green, decreased in adenoma tissues. In the sample axis, flat- and protruded-type adenomas were separated into two different trunks.
Genes the expression levels of which differed significantly in the flat-type adenoma group and the protruded-type adenoma group (Mann–Whitney U-test)
|
|
|
|
| |
|---|---|---|---|---|
| PMS1 | U13695 | DNA repair or protection | 0.0136 | P<F |
| nm23 | X17620 | Tumour suppressor | 0.0004 | P<F |
| p21 | U03106 | CDK inhibitor | 0.001 | P<F |
| FAK | L13616 | Cell signalling | 0.0017 | P<F |
| Smad4 | U44378 | Tumour suppressor | 0.0429 | P<F |
| c-jun | J04111 | Oncogene | <0.0001 | P<F |
| ECGF1 | M63193 | Growth factor | <0.0001 | P<F |
| Erk1 | X60188 | Cell signalling | <0.0001 | P<F |
| GAK | D88435 | Cell signalling | <0.0001 | P<F |
| GSTP1 | X06547 | DNA repair or protection | <0.0001 | P<F |
| IGF-2 | M29645 | Growth factor | <0.0001 | P<F |
| Laminin | D37766 | Cell signalling | <0.0001 | P<F |
| MMP-15 | Z48482 | Extracellular matrix-degrading enzymes | <0.0001 | P<F |
| Mucin 3 | AF143371 | Glycoprotein | <0.0001 | P<F |
| Rho GDI | L20688 | Cell signalling | <0.0001 | P<F |
| TIMP1 | X03124 | Extracellular matrix-degrading enzymes | <0.0001 | P<F |
| HLA-DQ | U77589 | Human leucocyte antigen | 0.0003 | P>F |
| Cdc42 | M57298 | Cell cycle | <0.0001 | P>F |
| Egr-2 | X53700 | Transcription | <0.0001 | P>F |
| Eph | M18391 | Cell signalling | <0.0001 | P>F |
| Galectin-1 | J04456 | Extracellular matrix-degrading enzymes | <0.0001 | P>F |
| Gp130 | M57230 | Cell signalling | <0.0001 | P>F |
| GST-II | U77604 | DNA repair or protection | <0.0001 | P>F |
| MDR1 | AF016535 | Glycoprotein | <0.0001 | P>F |
| p120 | AF062324 | Cell signalling | <0.0001 | P>F |
| Ras-GAP | AF051311 | Cell signalling | <0.0001 | P>F |
| Rho 8 | X95282 | Cell signalling | <0.0001 | P>F |
| E1AF | D12765 | Transcription | 0.1488 | |
| iNOS | AB022318 | Angiogenesis | 0.1639 | |
| BMP-4 | D30751 | Growth factor | 0.1966 | |
| MUC-2 | M74027 | Glycoprotein | 0.4107 | |
| M94151 | Cell adhesion | 0.5478 | ||
F=flat-type adenoma group; P=protruded-type adenoma group.
Genes the expression levels of which differed significantly in the early invasive carcinoma group and the protruded-type (28 genes) or flat-type (18 genes) adenoma group (Mann-Whitney U-test)
|
|
|
|
| ||
|---|---|---|---|---|---|
| BMP-4 | D30751 | 0.6128 | 0.2968 | ||
| Cdc42 | M57298 | 0.001 | CA<AD (P) | 0.0122 | CA>AD (F) |
| c-jun | J04111 | <0.0001 | CA>AD (P) | 0.0135 | CA>AD (F) |
| E1AF | D12765 | 0.0086 | CA>AD (P) | 0.13 | |
| ECGF1 | M63193 | <0.0001 | CA>AD (P) | 0.0002 | CA>AD (F) |
| Egr-2 | X53700 | <0.0001 | CA<AD (P) | 0.3423 | |
| Eph | M18391 | 0.0005 | CA<AD (P) | 0.7903 | |
| Erk1 | X60188 | <0.0001 | CA>AD (P) | 0.0276 | CA<AD (F) |
| FAK | L13616 | 0.0304 | CA>AD (P) | 0.4033 | |
| GAK | D88435 | 0.0227 | CA<AD (P) | <0.0001 | CA<AD (F) |
| Galectin-1 | J04456 | 0.704 | 0.0027 | CA>AD (F) | |
| Gp130 | M57230 | <0.0001 | CA<AD (P) | 0.9093 | |
| GST-II | U77604 | <0.0001 | CA<AD (P) | 0.8197 | |
| GSTP1 | X06547 | <0.0001 | CA>AD (P) | 0.0006 | CA>AD (F) |
| HLA-DQ | U77589 | 0.1489 | 0.0682 | ||
| IGF-2 | M29645 | 0.0034 | CA>AD (P) | 0.5937 | |
| iNOS | AB022318 | 0.0402 | CA>AD (P) | 0.0098 | CA>AD (F) |
| Laminin | D37766 | 0.0016 | CA>AD (P) | 0.0001 | CA<AD (F) |
| MDR1 | AF016535 | <0.0001 | CA<AD (P) | 0.4941 | |
| MMP-15 | Z48482 | 0.025 | CA>AD (P) | 0.0627 | |
| MUC-2 | M74027 | 0.0044 | CA<AD (P) | 0.0334 | CA<AD (F) |
| Mucin 3 | AF143371 | <0.0001 | CA>AD (P) | 0.0227 | CA<AD (F) |
| nm23 | X17620 | <0.0001 | CA>AD (P) | 0.0001 | CA>AD (F) |
| p120 | AF062324 | <0.0001 | CA<AD (P) | 0.4941 | |
| p21 | U03106 | 0.7324 | 0.0402 | CA<AD (F) | |
| PMS1 | U13695 | 0.0044 | CA<AD (P) | 0.0002 | CA<AD (F) |
| Ras-GAP | AF051311 | <0.0001 | CA<AD (P) | 0.7324 | |
| Rho 8 | X95282 | <0.0001 | CA<AD (P) | 0.8494 | |
| Rho GDI | L20688 | <0.0001 | CA>AD (P) | 0.0304 | CA>AD (F) |
| Smad4 | U44378 | <0.0001 | CA>AD (P) | <0.0001 | CA>AD (F) |
| TIMP1 | X03124 | <0.0001 | CA>AD (P) | 0.0024 | CA>AD (F) |
| M94151 | 0.0014 | CA<AD (P) | 0.0151 | CA<AD (F) | |
CA=early invasive carcinoma group; AD (P)=protruded-type adenoma group; AD (F)=flat-type adenoma group.